Active Investments

Aclaris Therapeutics
Specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies. (NASDAQ: ACRS)
Aerie Pharmaceuticals
Clinical-stage biotechnology company dedicated to the discovery and development of novel treatments for glaucoma. (NASDAQ: AERI)
Alimera Sciences
Specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. (NASDAQ: ALIM)
Amarin
Focused on improving the treatment of cardiovascular disease. The company’s cardiovascular programs capitalize on its expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular disease. (NASDAQ: AMRN)
Amplyx Pharmaceuticals
Amplyx Pharmaceuticals is developing novel, broad-spectrum antifungal agents for the treatment of life-threatening invasive fungal infections due to candida, aspergillus and rare molds.
Anthera Pharmaceuticals
Focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. (NASDAQ: ANTH)
Antiva
Develop creatively designed therapeutics that dramatically improve health outcomes for patients suffering from diseases caused by HPV and other viruses.
Apellis
Apellis Pharmaceuticals is a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases.
Ascendis Pharma
Ascendis Pharma develops differentiated prodrug versions of high-value protein drugs, such as growth hormone. (NASDAQ: ASND)
aTyr Pharma
Focused on the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. (NASDAQ: LIFE)
Audentes Therapeutics
Committed to the development and commercialization of innovative new treatments for people with serious, rare diseases through the application of gene therapy technology. (NASDAQ: BOLD)
Auris Medical
Prevention or treatment of inner ear disorders, for acute inner ear tinnitus and for acute inner ear hearing loss. (NASDAQ: EARS)
BioClin Therapeutics
Our strategy is to develop biologics for medical conditions where there has been no approved or satisfactory therapy. Our lead product, B-701, is a human antibody targeting FGFR3 (fibroblast growth factor receptor 3) being developed as a treatment for metastatic bladder cancer and achondroplasia (dwarfism).
Catalyst Biosciences
Creating novel catalytic biopharmaceutical products based on engineered human proteases.
Checkmate Pharmaceuticals
Developing novel approach to specifically activating the immune system to recognize and ultimately destroy tumor cells.
Chiasma
Late-stage biotech developing an oral drug candidate for acromegaly. (NASDAQ: CHMA)
Coherus Biosciences
A leading developer of high-quality therapeutics with a robust pipeline of biosimilar products. (NASDAQ: CHRS)
Dauntless Pharmaceuticals
Biopharmaceutical company focused on the development of specialty drugs.
Edge Therapuetics
Develops commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions. (NASDAQ: EDGE)
Entasis Therapeutics
With our unique approach, we are developing and advancing novel antibacterials to treat serious drug-resistant bacterial infections.
First Aid Shot Therapy
Focused on the development and commercialization of a comprehensive portfolio of OTC pharmaceutical products in liquid 'shot' format.
Galera Therapeutics
Galera Therapeutics is a private clinical-stage biotech company focused on the development of breakthrough drugs targeting the oxygen metabolic pathways.
Histogenics
Combining cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. (NASDAQ: HSGX)
Hyperion Therapeutics
Focused on the development of treatments that address critical unmet needs in the areas of gastroenterology and hepatology. (NADSAQ: HPTX)
Innocoll
Developing and manufacturing a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies. (NASDAQ: INNL)
Iterum Therapeutics
Iterum Therapeutics is a clinical-stage pharmaceutical company dedicated to developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world.
Marinus Pharmaceuticals
Dedicated to the reformulation, development, and commercialization of novel drugs to treat serious neurological, psychiatric, and pain disorders including epilepsy. (NASDAQ: MRNS)
Medeor Therapeutics
Medeor Therapeutics is a private, late clinical stage, biotechnology company dedicated to the discovery, development, and commercialization of transformative and personalized cellular immunotherapies.
Merus
Clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics to treat and potentially cure cancer patients.
Mirna Therapeutics
Developing tumor suppressor microRNAs (miRNAs) to kill cancer cells by regaining control over multiple oncogenic pathways. (NASDAQ: MIRN)
Natera
Develops and commercializes non-invasive methods for analyzing DNA.
NuCana
Developing and commercialising novel anti-cancer medicines including next generation nucleotide prodrugs. (NASDAQ: NCNA)
ObsEva
Dedicated to the development of innovative drugs for women’s reproductive medicine including preterm labor. (NASDAQ: OBSV)
Ocera
Focused on the development of drugs to treat a broad range of gastrointestinal and liver diseases. (NASDAQ: OCRX)
Ophthotech Corporation
Specializing in the development of novel therapeutics to treat diseases of the eye. (NASDAQ: OPHT)
Principia Biopharma
Focused on discovering and developing first-in-class small molecule drugs within the fields of autoimmune disease and oncology that are potent and safe.
Prothena
Advancing and developing novel antibodies for broad range of diseases involving protein misfolding or cell adhesion, including amyloidosis. (NASDAQ: PRTA)
Spark Therapeutics
Focused on developing curative, one-time gene therapy products including lead gene therapy candidate, for RPE65-related blindness. (NASDAQ: ONCE)
Synlogic
Synlogic is dedicated to bringing innovative living medicines to patients by using the tools and principles of synthetic biology to genetically re-program beneficial bacteria.
Versartis
Developing therapeutics for the treatment of endocrine disorders, including human growth hormones. (NASDAQ: VSAR)
Y-mAbs
Y-mAbs Therapeutics, Inc (YmAbs) is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets based on a range of technologies licensed from Memorial Sloan Kettering Cancer Center (“MSK”) under an exclusive worldwide license and research collaboration agreement.
Ziarco
Ziarco is a private, clinical stage biotechnology company developing products to treat chronic inflammatory diseases with a focus on inflammatory skin disorders, in particular atopic dermatitis and psoriasis. These diseases impact the well-being of millions of children and adults globally by severely reducing quality of life.
ZS Pharma
Focused on the treatment of kidney and liver diseases including hyperkalemia. (NASDAQ: ZSPH)